NCT05389267: Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 120 planned
- Started
- 5 Jul 2022
- Primary completion
- 31 Dec 2024
- Arms
- T4090
- Results
- None posted
- 25 May 2022: Trial registered
- 5 Jul 2022: Trial started